Technology

MEI Pharma

$2.99
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.11 (+3.82%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell MEI Pharma and other stocks, options, and ETFs commission-free!

About MEIP

MEI Pharma, Inc. Common Stock, also called MEI Pharma, is a pharmaceutical company, which engages in the clinical development of therapies for cancer. Its drug candidates include Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA. The listed name for MEIP is MEI Pharma, Inc. Common Stock.

CEO
Daniel P. Gold
Employees
51
Headquarters
San Diego, California
Founded
2000
Market Cap
352.80M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
895.13K
High Today
$2.99
Low Today
$2.86
Open Price
$2.91
Volume
461.07K
52 Week High
$4.46
52 Week Low
$0.72

Collections

MEIP Earnings

-$0.26
-$0.17
-$0.09
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Expected Feb 4, After Hours

You May Also Like

TINV+
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure